Compare Biocon with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs CIPLA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON CIPLA BIOCON /
CIPLA
 
P/E (TTM) x 40.1 29.4 136.3% View Chart
P/BV x 5.3 4.1 127.5% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 BIOCON    CIPLA
EQUITY SHARE DATA
    BIOCON
Mar-21
CIPLA
Mar-21
BIOCON /
CIPLA
5-Yr Chart
Click to enlarge
High Rs488879 55.5%   
Low Rs275411 66.9%   
Sales per share (Unadj.) Rs59.2237.6 24.9%  
Earnings per share (Unadj.) Rs7.729.8 25.9%  
Cash flow per share (Unadj.) Rs13.743.0 31.8%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Avg Dividend yield %00.8 0.0%  
Book value per share (Unadj.) Rs62.3226.7 27.5%  
Shares outstanding (eoy) m1,200.00806.46 148.8%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x6.42.7 237.2%   
Avg P/E ratio x49.421.6 228.3%  
P/CF ratio (eoy) x27.915.0 186.0%  
Price / Book Value ratio x6.12.8 215.3%  
Dividend payout %016.8 0.0%   
Avg Mkt Cap Rs m457,350519,826 88.0%   
No. of employees `000NANA-   
Total wages/salary Rs m17,41032,518 53.5%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m71,058191,596 37.1%  
Other income Rs m6,0522,698 224.3%   
Total revenues Rs m77,110194,294 39.7%   
Gross profit Rs m13,14542,487 30.9%  
Depreciation Rs m7,15110,677 67.0%   
Interest Rs m5771,607 35.9%   
Profit before tax Rs m11,46932,901 34.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2158,888 24.9%   
Profit after tax Rs m9,25424,013 38.5%  
Gross profit margin %18.522.2 83.4%  
Effective tax rate %19.327.0 71.5%   
Net profit margin %13.012.5 103.9%  
BALANCE SHEET DATA
Current assets Rs m76,004132,095 57.5%   
Current liabilities Rs m42,10145,916 91.7%   
Net working cap to sales %47.745.0 106.1%  
Current ratio x1.82.9 62.8%  
Inventory Days Days13768 201.9%  
Debtors Days Days637 952.8%  
Net fixed assets Rs m106,142116,277 91.3%   
Share capital Rs m6,0001,613 372.0%   
"Free" reserves Rs m68,728181,232 37.9%   
Net worth Rs m74,728182,844 40.9%   
Long term debt Rs m29,61612,028 246.2%   
Total assets Rs m182,146248,372 73.3%  
Interest coverage x20.921.5 97.2%   
Debt to equity ratio x0.40.1 602.5%  
Sales to assets ratio x0.40.8 50.6%   
Return on assets %5.410.3 52.3%  
Return on equity %12.413.1 94.3%  
Return on capital %11.517.7 65.2%  
Exports to sales %031.3 0.0%   
Imports to sales %7.210.9 65.6%   
Exports (fob) Rs mNA59,951 0.0%   
Imports (cif) Rs m5,08420,911 24.3%   
Fx inflow Rs m11,79168,051 17.3%   
Fx outflow Rs m5,08420,911 24.3%   
Net fx Rs m6,70747,140 14.2%   
CASH FLOW
From Operations Rs m11,59737,552 30.9%  
From Investments Rs m-36,247-23,872 151.8%  
From Financial Activity Rs m25,640-13,299 -192.8%  
Net Cashflow Rs m723509 142.0%  

Share Holding

Indian Promoters % 39.7 13.5 294.5%  
Foreign collaborators % 20.9 20.1 103.8%  
Indian inst/Mut Fund % 24.0 48.6 49.3%  
FIIs % 15.6 26.6 58.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.4 66.4 59.3%  
Shareholders   347,911 418,584 83.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    AUROBINDO PHARMA    

Yellow Ad

Advertisement

A One Stock Gift in 1990 Turns into Rs 130 Crores

In 2017, Ravi made headlines by calling a leading business news channel with a surprising announcement - his grandfather had left him 20,000 shares of only one stock.

And on the day of his call - these shares were worth Rs 130 crore.

Can you guess which is this company?

It's MRF.

Ravi's story is one of the amazing stories of becoming Crorepati from a single stock.

But the question is, how to find that one stock with crorepati potential?

To find the answer to this million-dollar question, join our 'One Stock Crorepati' MEGA summit on 30th June, where we will reveal details of what we call a potential 'crorepati' stock...

Learn more



Today's Market

Sensex Zooms 462 Points, Nifty Ends Near 15,700; Auto & FMCG Stocks Rally(Closing)

Indian share markets ended the week on a firm note tracking positive global cues.

Related Views on News

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Cipla Shares Tank Despite Strong Earnings (Views On News)

Aug 6, 2021

The stock fell 3.5% even as the company reported numbers higher than analysts' expectations.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Why Tata Power Share Price is Falling(Views On News)

Jun 14, 2022

Here's why shares of Tata Power have fallen in recent days.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

When Will the Stock Market Recover?(Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jun 24, 2022 (Close)

TRACK BIOCON

BIOCON - ANUH PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS